AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

13.740

+0.0400.29%

Volume:1.55M

Turnover:21.28M

Market Cap:4.65B

PE:214.08

High:14.150

Open:14.010

Low:13.590

Close:13.700

52wk High:31.970

52wk Low:13.300

Shares:338.72M

Float Shares:275.41M

Volume Ratio:1.17

T/O Rate:0.56%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.064

EPS(LYR):0.227

ROE:3.14%

ROA:2.08%

PB:7.33

PE(LYR):60.57

Loading ...

Overview Company News Filings

Does Telix (ASX:TLX) And Varian’s PSMA-PET Tie-Up Redefine Its Radiotherapy Moat?

Simply Wall St.

Telix Pharmaceuticals Faces Class Action Lawsuit Over Alleged Securities Fraud

Telix Pharmaceuticals (ASX:TLX) Valuation Check as ProstACT Global Phase 3 Trial Progresses to Part 2

Simply Wall St.

BRIEF-Telix And Varian Announce Strategic Theranostics-Ebrt Clinical Collaboration

Telix Pharmaceuticals Partners with Varian to Advance Precision Cancer Therapy

Telix Pharmaceuticals Ltd - Focus on Psma-Pet Imaging for Prostate Cancer Radiotherapy

THOMSON REUTERS

Telix Pharmaceuticals Faces Class Action Over Alleged Securities Fraud

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

ASX Value Picks Eagers Automotive And 2 Other Stocks Below Estimated Worth

Simply Wall St.

Telix Pharmaceuticals Faces Investor Class Action Over Alleged Securities Fraud

Telix Pharmaceuticals (ASX:TLX) Valuation After ZIRCON-X Data Highlights TLX250-CDx’s Potential Clinical and Commercial Impact

Simply Wall St.

Telix Pharmaceuticals Faces Investor Lawsuit Alleging Securities Fraud

Telix Pharmaceuticals Faces Shareholder Class Action Over Alleged Securities Fraud

BUZZ-Citi sees near-term regulatory events boosting shares of Australia's Telix Pharmaceuticals

ASX Biggest Gainers

MT Newswires Live

3 ASX Growth Stocks With High Insider Ownership Growing Earnings Up To 47%

Simply Wall St.

ASX Top Gainers

MT Newswires Live

Telix Pharmaceuticals Opens First Cyclotron Facility in Japan

Telix Study Finds TLX250-CDx PET/CT Alters Clinical Management for Nearly Half of Renal Mass Patients

Thor Medical Announces Strategic Supply Agreement With Telix Pharmaceuticals For Thorium-228

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":13.74,"timestamp":1765516320000,"preClose":13.7,"halted":0,"volume":1545878,"delay":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.06418206996206875,"marketStatus":"Not Yet Opened","change":0.04,"latestTime":"12-12 16:12:00 AEDT","open":14.01,"high":14.15,"low":13.59,"amount":21275390,"amplitude":0.040876,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.06418206996206875,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1765753200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":13.7,"openAndCloseTimeList":[[1765494000000,1765515600000]],"volumeRatio":1.168132640146212,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.08%","roe":"3.14%","lyrEps":0.226848,"volumeRatio":1.168132640146212,"shares":338721355,"dividePrice":0,"high":14.15,"amplitude":0.040876,"preClose":13.7,"low":13.59,"week52Low":13.3,"pbRate":"7.33","psRate":"4.65","week52High":31.97,"institutionHeld":0,"latestPrice":13.74,"eps":0.06418206996206875,"divideRate":0,"volume":1545878,"delay":0,"ttmEps":0.06418206996206875,"open":14.01,"prevYearClose":24.61,"prevWeekClose":13.74,"prevMonthClose":15.22,"prevQuarterClose":14.57,"fiveDayClose":14.81,"twentyDayClose":14.13,"sixtyDayClose":14.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null},{"date":"2024-02-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-10-18","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1697583600000,"name":null,"time":"","dateTimestamp":1697547600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2590331577","title":"Does Telix (ASX:TLX) And Varian’s PSMA-PET Tie-Up Redefine Its Radiotherapy Moat?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590331577","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590331577?lang=en_us&edition=fundamental","pubTime":"2025-12-12 12:40","pubTimestamp":1765514409,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently announced a clinical collaboration with Varian, a Siemens Healthineers company, to combine its theranostic radiopharmaceuticals with external beam radiation therapy, initially focusing on PSMA-PET imaging in prostate cancer. \nThis tie-up could broaden the role of nuclear medicine in radiation oncology by using Telix’s Gozellix and Illuccix to sharpen patient selection and treatment planning. \nNext, we’ll examine how this Varian collaboration around...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-telix-asxtlx-and-varians-psma-pet-tie-up-redefine-its-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-telix-asxtlx-and-varians-psma-pet-tie-up-redefine-its-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","TLX.AU","BK7067","BK4139"],"gpt_icon":0},{"id":"2590151512","title":"Telix Pharmaceuticals Faces Class Action Lawsuit Over Alleged Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2590151512","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590151512?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:54","pubTimestamp":1765457654,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who suffered losses between February 21, 2025, and August 28, 2025. The complaint alleges that Telix Pharmaceuticals and its executives made false or misleading statements regarding the progress of its prostate cancer therapeutic candidates and overstated the quality of its supply chain and business partners. As a result, the lawsuit claims that statements about the company's business, operations, and prospects were materially false and lacked a reasonable basis during the relevant period. The legal action seeks to recover damages for affected investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL23zvtQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2590598517","title":"Telix Pharmaceuticals (ASX:TLX) Valuation Check as ProstACT Global Phase 3 Trial Progresses to Part 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2590598517","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590598517?lang=en_us&edition=fundamental","pubTime":"2025-12-11 10:27","pubTimestamp":1765420032,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has dosed the first patient in Part 2 of its ProstACT Global Phase 3 trial for TLX591 in advanced prostate cancer, a key step that can reshape future value expectations.\nSee our latest analysis for Telix Pharmaceuticals.\nThis milestone comes after a tough stretch for investors, with the share price down sharply on a year to date basis even as the 3-year total shareholder return of 97.18 percent still points to strong long term wealth creation. This suggests...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-valuation-check-as-prostact-glo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-valuation-check-as-prostact-glo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DCF","TLX.AU","TLX","BK7067"],"gpt_icon":0},{"id":"2590581784","title":"BRIEF-Telix And Varian Announce Strategic Theranostics-Ebrt Clinical Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2590581784","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590581784?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:03","pubTimestamp":1765368230,"startTime":"0","endTime":"0","summary":"BRIEF-Telix And Varian Announce Strategic Theranostics-Ebrt Clinical CollaborationDec 10 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:TELIX AND VARIAN ANNOUNCE STRATEGIC THERANOSTICS-EBRT CLINICAL COL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA1LTLH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2590581447","title":"Telix Pharmaceuticals Partners with Varian to Advance Precision Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590581447","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590581447?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:00","pubTimestamp":1765368027,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL34K7sg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","BK7067","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014039.USD","LU2210150020.SGD","BK4112","SG9999014021.USD","BK4585","SG9999014013.SGD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","SG9999014005.SGD","TLX.AU","LU2210149790.SGD"],"gpt_icon":0},{"id":"2590581470","title":"Telix Pharmaceuticals Ltd - Focus on Psma-Pet Imaging for Prostate Cancer Radiotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590581470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590581470?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:00","pubTimestamp":1765368001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUA1LTLH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2589912358","title":"Telix Pharmaceuticals Faces Class Action Over Alleged Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2589912358","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589912358?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:45","pubTimestamp":1765197929,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who incurred losses between February 21, 2025 and August 28, 2025. The complaint alleges that Telix Pharmaceuticals and its executives made false and misleading statements by overstating the progress of its prostate cancer therapeutic candidates and the quality of its supply chain and partners. As a result, statements about the company's business, operations, and prospects were allegedly materially false and lacked a reasonable basis during the relevant period. The lawsuit seeks to recover damages for affected investors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL3B6ytG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2589060328","title":"ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2589060328","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589060328?lang=en_us&edition=fundamental","pubTime":"2025-12-08 06:08","pubTimestamp":1765145280,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ --Telix Pharmaceuticals Limited  today announces that the first patienthas been dosed in Part 2  of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591  in patients with metastatic castration resistant prostate cancer . The patient was dosed at the Australian Prostate Centre  in Melbourne, Australia.ProstACT Global is the first Phase 3 trial to combine aPSMA[1]-targeted radio antibody-drug conjugate  therapy administered together with Standard of Care  versus SOC alone. Part 2 of ProstACT Global will enroll approximately 490 patients and is currently recruiting patients in Australia, New Zealand and Canada.As previously agreed with FDA and disclosed to the market, Telix will submit Part 1 data to the United States  Food and Drug Administration  to enable clearance to expand Part 2 of the trial to U.S. sites. A public disclosure of preliminary results from Part 1 of the study will","market":"hk","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prostact-global-phase-3-update-first-patient-dosed-in-randomized-treatment-expansion-part-1-readout-plans-confirmed-302634831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","LU2456880835.USD","XJO.AU","CTA","LU0882574139.USD","LU1674673691.USD","BK7095","LU0077335932.USD","XAO.AU","LU2236285917.USD","LU0786609619.USD","EMA.AU","SEC.AU","LU1935043023.USD","LU0149725797.USD","BK7067","LU1066051225.USD","LU1935043536.SGD","TLX","TLX.AU","RLT.AU","BK4543","BK7129","ASX.AU","LU0314104364.USD","LU1935042991.SGD","LU1066051498.USD","ASX","BK4141","LU1935042488.USD","LU2237443622.USD","BK4526","XKO.AU","LU2237443549.SGD","APC","LU2083900584.USD","LU0170899867.USD","LU1066053197.SGD","LU2237443382.USD","APC.AU","LU1366192091.USD","BK4139","LU1496350171.SGD","LU2237443978.SGD","LU1718418525.SGD","LU2420271590.USD","BK7142","EMA","LU0053666078.USD","LU1066051811.HKD"],"gpt_icon":0},{"id":"2589870801","title":"ASX Value Picks Eagers Automotive And 2 Other Stocks Below Estimated Worth","url":"https://stock-news.laohu8.com/highlight/detail?id=2589870801","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589870801?lang=en_us&edition=fundamental","pubTime":"2025-12-08 03:04","pubTimestamp":1765134263,"startTime":"0","endTime":"0","summary":"As the Australian stock market experiences a mix of optimism and caution, highlighted by fluctuating indices and recent corporate announcements, investors are keenly observing potential opportunities amidst the volatility. In such an environment, identifying undervalued stocks becomes crucial as they may offer attractive entry points for those looking to capitalize on discrepancies between current prices and intrinsic value.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/4411000-choice1-main-header/1585186879929","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/4411000-choice1-main-header/1585186879929"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/retail/asx-snl/supply-network-shares/news/asx-value-picks-eagers-automotive-and-2-other-stocks-below-e","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/retail/asx-snl/supply-network-shares/news/asx-value-picks-eagers-automotive-and-2-other-stocks-below-e","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK7086","BK7002","IMM.AU","XJO.AU","NWH.AU","BK7154","APE.AU","BK7137","BK7508","BK7060","BK7062","CMW.AU","BK7078","CSX.AU","BK7084","TLX.AU","GYG.AU","LGI.AU","BK7007","XKO.AU","SNL.AU","SPZ.AU","BK7055","RPL.AU","XAO.AU","BK7047","BK7143","BET.AU","ART.AU","BK7122"],"gpt_icon":0},{"id":"2589164892","title":"Telix Pharmaceuticals Faces Investor Class Action Over Alleged Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2589164892","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589164892?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:45","pubTimestamp":1764938716,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who suffered losses between February 21, 2025, and August 28, 2025. The complaint alleges that the company made false or misleading statements by overstating progress on its prostate cancer therapeutic candidates and the quality of its supply chain and partners. As a result, the lawsuit claims that Telix's public statements about its business, operations, and prospects were materially false and lacked a reasonable basis during the relevant period. The legal action seeks to recover losses for affected shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this ne","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL66ZqqL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2588607073","title":"Telix Pharmaceuticals (ASX:TLX) Valuation After ZIRCON-X Data Highlights TLX250-CDx’s Potential Clinical and Commercial Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2588607073","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588607073?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:16","pubTimestamp":1764796575,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) just released ZIRCON-X study data showing its TLX250-CDx kidney imaging agent could have changed clinical decisions for almost half of patients, with more than 20% potentially avoiding invasive biopsy.\nSee our latest analysis for Telix Pharmaceuticals.\nDespite the latest ZIRCON-X update highlighting the potential commercial impact of TLX250-CDx, Telix’s recent share price performance has been choppy, with a 1 month share price return of minus 9.68 percent and a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-valuation-after-zircon-x-data-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-valuation-after-zircon-x-data-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX","BK4139","DCF","TLX.AU"],"gpt_icon":0},{"id":"2588592046","title":"Telix Pharmaceuticals Faces Investor Lawsuit Alleging Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2588592046","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588592046?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:45","pubTimestamp":1764765912,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who suffered losses between February 21, 2025 and August 28, 2025. The complaint alleges that Telix made false statements and concealed material information regarding the progress of its prostate cancer therapeutic candidates and the quality of its supply chain and partners. According to the lawsuit, these alleged misrepresentations caused statements about the company's business, operations, and prospects to be materially false or misleading during the relevant period. The legal action seeks to recover losses for affected shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content us","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLz012c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2588706157","title":"Telix Pharmaceuticals Faces Shareholder Class Action Over Alleged Securities Fraud","url":"https://stock-news.laohu8.com/highlight/detail?id=2588706157","media":"Reuters","labels":["shareholding","policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588706157?lang=en_us&edition=fundamental","pubTime":"2025-12-02 03:42","pubTimestamp":1764618132,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who incurred losses due to alleged securities fraud between February 21, 2025 and August 28, 2025. The legal action seeks to recover damages for shareholders affected during this period. The case is being handled by the law firm Levi & Korsinsky, which has a history of representing investors in complex securities litigation and securing significant settlements for clients. Investors who experienced losses during the specified timeframe are encouraged to come forward for more information regarding their rights and potential claims.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL51PfFk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Telix Pharmaceuticals Faces Shareholder Class Action Over Alleged Securities Fraud","news_tag":"shareholding,policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2586220815","title":"BUZZ-Citi sees near-term regulatory events boosting shares of Australia's Telix Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2586220815","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586220815?lang=en_us&edition=fundamental","pubTime":"2025-11-28 05:00","pubTimestamp":1764277257,"startTime":"0","endTime":"0","summary":"BUZZ-Citi sees near-term regulatory events boosting shares of Australia's Telix Pharmaceuticals** Citi says investor confidence for biopharmaceutical firm Telix Pharmaceuticals TLX.AX hinges on FDA resubmission of Pixclara, and the safety data from Phase 3 ProstACT Global trial for TLX591** Pixclara is a brain cancer imaging agent, while TLX591 is a prostate cancer drug candidate** Brokerage believes best-case scenarios for both events - Class 1 submission for Pixclara and perfect commentary on 591, not needed for investors to \"warm up to the stock\"** Class 1 resubmission to FDA is subject to a two-month review cycle** Brokerage expects both events in 2H, estimating Class 2 submission for Pixclara, which entails longer six-month review period** Citi views the 30-patient safety run-in setup as favourable from a design perspective for 591, even if its inclusion was FDA-motivated** All 12 analysts rate the stock \"buy\" or higher; their median PT is A$27.26 – LSEG data** YTD, stock down 37.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nL6N3X30W7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2586213808","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2586213808","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586213808?lang=en_us&edition=fundamental","pubTime":"2025-11-27 11:34","pubTimestamp":1764214457,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest gains on Thursday.Reece Limited : +4%, AU$12.75Pinnacle Investment : +4%, AU$17.64Nexgen : +3%, AU$13.16NRW Holdings : +3%, AU$5.28DPM Metals : +3%, AU$41.23Life360 : +3%, AU$40.97Premier Investments : +2%, AU$17.99Regis Resources : +2%, AU$7.22Telix Pharmaceuticals : +2%, AU$15.30Megaport : +2%, AU$14.47","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PMV.AU","NWH.AU","BK7067","BK7016","BK7055","360.AU","NXG.AU","BK7503","BK7043","BK7083","PNI.AU","RRL.AU","BK7104","REH.AU","MP1.AU","BK7031","BK7062","TLX.AU","DPM.AU","BK7021"],"gpt_icon":0},{"id":"2586047444","title":"3 ASX Growth Stocks With High Insider Ownership Growing Earnings Up To 47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586047444","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586047444?lang=en_us&edition=fundamental","pubTime":"2025-11-26 03:08","pubTimestamp":1764097687,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a mixed landscape, with materials gaining ground and financials lagging, investors are keenly observing growth opportunities amidst fluctuating conditions. In such an environment, stocks with high insider ownership can be particularly appealing as they often indicate confidence in the company's future prospects.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-eol/energy-one-shares/news/3-asx-growth-stocks-with-high-insider-ownership-growing-earn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-eol/energy-one-shares/news/3-asx-growth-stocks-with-high-insider-ownership-growing-earn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XAO.AU","EMR.AU","WZR.AU","BK7095","BK4139","LM8.AU","BK7036","EOL.AU","BK7093","BK7116","BK7506","3DP.AU","BK7142","PH2.AU","AV1.AU","PWH.AU","TLX","IR1.AU","BK7016","EIQ.AU","BK7051","BK7104","TLX.AU","TTT.AU","BK7067","NWF.AU","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2586417282","title":"ASX Top Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2586417282","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586417282?lang=en_us&edition=fundamental","pubTime":"2025-11-25 10:08","pubTimestamp":1764036531,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest gains on Tuesday.Ramsay Health Care : +12%, AU$35.67Ora Banda Mining : +7%, AU$1.247Telix Pharmaceuticals : +6%, AU$14.78Resolute Mining : +6%, AU$1.085Greatland Resources : +6%, AU$7.93Life360 : +5%, AU$41.21Almonty Industries : +5%, AU$9Temple & Webster Group : +4%, AU$19.67Paladin Energy : +4%, AU$7.77Capstone : +4%, AU$12.7","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RSG.AU","BK6045","GGP.AU","BK7083","BK7049","BK7016","OBM.AU","CSC.AU","TLX.AU","BK7110","TPW.AU","PDN.AU","BK7104","RHC.AU","BK7509","BK7107","BK7113","BK7506","BK7067","360.AU","AII.AU","C06.SI","BK6520","BK7095"],"gpt_icon":0},{"id":"2585860199","title":"Telix Pharmaceuticals Opens First Cyclotron Facility in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2585860199","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585860199?lang=en_us&edition=fundamental","pubTime":"2025-11-21 13:22","pubTimestamp":1763702568,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL30LFMl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2584920065","title":"Telix Study Finds TLX250-CDx PET/CT Alters Clinical Management for Nearly Half of Renal Mass Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2584920065","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584920065?lang=en_us&edition=fundamental","pubTime":"2025-11-20 03:00","pubTimestamp":1763578815,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. has announced results from the ZIRCON-X study, which evaluated the impact of TLX250-CDx  PET/CT imaging on clinical decision-making in patients with indeterminate renal masses . The non-interventional, prospective, post-hoc study analyzed imaging data from the parent Phase 3 ZIRCON trial, involving 294 patients. Findings indicate that almost half of the patients imaged with TLX250-CDx would have undergone a change in clinical management compared to standard of care imaging. Over 20% of those with a change in management could have potentially avoided invasive biopsy. The results are scheduled to be presented at the 26th Annual Meeting of the Society of Urologic Oncology , taking place in Phoenix, AZ, from December 2 to 5, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sho","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL3ls3bv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK7067","TLX.AU","BK4585","BK4112","NDAQ","LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4588","IE00BKPKM429.USD","LU2095319765.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2584926180","title":"Thor Medical Announces Strategic Supply Agreement With Telix Pharmaceuticals For Thorium-228","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926180","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926180?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:48","pubTimestamp":1763570936,"startTime":"0","endTime":"0","summary":"Nov 6 (Reuters) - Thor Medical ASA ::*THOR MEDICAL AND TELIX PHARMACEUTICALS SIGN STRATEGIC SUPPLY AGREEMENT FOR THORIUM-228*THOR MEDICAL ASA - TO SUPPLY THORIUM-228 TO TELIX FOR FIVE YEARS*THOR MEDIC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDc6gWTR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":127,"code":"91000000","status":"200"}]}}